Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glowing dye could help surgeons see hidden breast cancer

NCT ID NCT06713681

Diagnosis Sponsor: Yunnan Cancer Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study tested a special dye called TTP-ICG that sticks to breast cancer cells. After removing tissue, doctors soaked it in the dye and used a special camera to see if cancer cells were left at the edges or in lymph nodes. The goal was to help surgeons know right away if they got all the cancer out, reducing the need for second surgeries. The study involved 59 women with breast lumps.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TTP-ICG (a dye that sticks to cancer cells)
What this could lead to
If successful, this could give surgeons a quick, accurate way to check during surgery whether all cancer has been removed and if lymph nodes are affected, potentially reducing repeat surgeries.
What could go wrong
This was a small, completed study with 59 people, so results may not apply to everyone. The dye's accuracy in real-time surgery still needs more testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

59 people

The number who actually took part.

Started

May 2024

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigation involved 48 breast cancer patients and 11 fibroadenoma patients , aged 18 to 75 years, who have been assessed to have resectable breast nodules or masses and are scheduled to undergo surgery. During the surgery, the resected tumors and lymph nodes were incubated with the TTP-ICG solution, and NIR-II fluorescence images from the tissues were collected.

Ages

18 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients between 18-75 years of age * Female * Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment * Good operative candidate * Subject capable of giving informed consent and participating in the process of consent Exclusion Criteria: * Patients unable to participate in the consent process * Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc * Other conditions that the researcher considers inappropriate to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Margins of Excision

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Margins of excision Sentinel lymph node

Contacts and locations

Locations

  • Yunnan Cancer Hospital

    Kunming, Yunnan, 650118, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.